KVD 998052
Alternative Names: KV-998052; KVD-998052Latest Information Update: 12 Jun 2026
At a glance
- Originator Vantia Therapeutics
- Developer KalVista Pharmaceuticals
- Class Eye disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Plasma kallikrein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Adult respiratory distress syndrome
- No development reported Retinal oedema
Most Recent Events
- 11 Jun 2026 KalVista Pharmaceuticals has been acquired by Chiesi
- 28 Jun 2023 No recent reports of development identified for preclinical development in Retinal oedema in United Kingdom (PO)
- 28 Jun 2021 Preclinical trials in Adult respiratory distress syndrome in United Kingdom (PO), prior to June 2021